Abstract

Tumor biomarkers, the substances which are produced by tumors or the body’s responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecular biology technologies developed for the detection of tumor biomarkers. Herein, we summarize the discovery and development of tumor biomarkers, including the history of tumor biomarkers, the conventional and innovative technologies used for biomarker discovery and detection, the classification of tumor biomarkers based on tissue origins, and the application of tumor biomarkers in clinical cancer management. In particular, we highlight the recent advancements in biomarker-based anticancer-targeted therapies which are emerging as breakthroughs and promising cancer therapeutic strategies. We also discuss limitations and challenges that need to be addressed and provide insights and perspectives to turn challenges into opportunities in this field. Collectively, the discovery and application of multiple tumor biomarkers emphasized in this review may provide guidance on improved precision medicine, broaden horizons in future research directions, and expedite the clinical classification of cancer patients according to their molecular biomarkers rather than organs of origin.

Details

Title
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Author
Zhou, Yue 1 ; Tao, Lei 1   VIAFID ORCID Logo  ; Qiu, Jiahao 1 ; Xu, Jing 1 ; Yang, Xinyu 2 ; Zhang, Yu 3 ; Tian, Xinyu 1 ; Guan, Xinqi 1 ; Cen, Xiaobo 4   VIAFID ORCID Logo  ; Zhao, Yinglan 1   VIAFID ORCID Logo 

 Sichuan University, Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581) 
 Sichuan University, West China School of Pharmacy, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581) 
 Sichuan University, West China School of Pharmacy, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581); Tibet University, School of Medicine, Lhasa, China (GRID:grid.440680.e) (ISNI:0000 0004 1808 3254) 
 Sichuan University, Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581); Sichuan University, National Chengdu Center for Safety Evaluation of Drugs, State Key Laboratory of Biotherapy, West China Hospital, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581) 
Pages
132
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3056525095
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.